Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate!

Written by Kimberly Hicks

January 29, 2025 · Dewpoint Therapeutics

Dewpoint Therapeutics Nominates DPTX3496 as a Development Candidate for Colorectal, Breast, and Lung Cancers

DPTX3496 is Dewpoint's second development candidate targeting beta catenin in Wnt-driven cancers, using a condensate-modulating mechanism.

  • Oral, small molecule condensate modulator targeting beta catenin, aimed at colorectal cancer, triple negative breast cancer, and non-small cell lung cancer
  • Tumor regression and stasis reported in preclinical models, including patient-derived xenograft models, with good tolerability in animals
  • IND-enabling studies are underway, with an IND filing planned for the second half of 2025
  • IND-enabling work is being carried out with Evotec, and Dewpoint is partnering with ConcertAI on patient stratification
Read the full announcement

Source: Dewpoint Therapeutics. DPTX3496 is a preclinical, investigational compound and has not been approved by any regulatory authority. Timelines are forward-looking statements as of the announcement date.

Kimberly Hicks
Previous

Congratulations to Alnylam Pharmaceuticals on the FDA Approval of Amvuttra.